Pharma: Other News To Note
Tuesday, November 26, 2013
• Mallinckrodt Inc., of St. Louis, said the FDA extended the review of the new drug application (NDA) for Xartemis XR (oxycodone hydrochloride and acetaminophen) extended-release tablets, previously known as MNK-795, for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.